Evidence map›Paper›PMID 41154596›Full record

ArticleBiomolecules2025

Association of Plasma Placental Growth Factor with White Matter Hyperintensities in Alzheimer's Disease.

Kazuya Igarashi, Tamao Tsukie, Kazuo Washiyama, Kiyoshi Onda, Yuki Miyagi, Shoya Inagawa, Soichiro Shimizu, Akinori Miyashita, Osamu Onodera, Takeshi Ikeuchi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. New perspectives on VEGF signalling in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kazuya IgarashiDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
Tamao TsukieDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.ORCID 0009-0000-7958-8991
Kazuo WashiyamaDepartment of Neurosurgery, Niigata Rinko Hospital, Niigata 950-8725, Japan.
Kiyoshi OndaDepartment of Neurosurgery, Niigata Neurosurgical Hospital, Niigata 950-1101, Japan.
Yuki MiyagiDepartment of Geriatric Medicine, Tokyo Medical University, Tokyo 160-8402, Japan.
Shoya InagawaDepartment of Geriatric Medicine, Tokyo Medical University, Tokyo 160-8402, Japan.
Soichiro ShimizuDepartment of Geriatric Medicine, Tokyo Medical University, Tokyo 160-8402, Japan.
Akinori MiyashitaDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.ORCID 0000-0003-2508-9649
Osamu OnoderaDepartment of Neurology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.ORCID 0000-0003-3354-5472
Takeshi IkeuchiDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.ORCID 0000-0001-8828-8085
Kensaku KasugaDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.ORCID 0000-0002-2178-0769

Funding

Japan Society for the Promotion of Science (JSPS) KAKENHI 20K20497 and 23K18262MHLW Research on Dementia Program JPMH24GB1001
6 · The paper itself

Abstract

Autopsy studies have shown that Alzheimer's disease (AD) often coexists with cerebrovascular injury, affecting cognitive outcomes and the effectiveness of anti-amyloid-beta (Aβ) drugs. No fluid biomarkers of cerebrovascular injury have been identified yet. We investigated the association between white matter hyperintensities (WMH) severity and fluid biomarkers, including cerebrospinal fluid (CSF) neurofilament light chain and plasma placental growth factor (PlGF) levels. This study included 242 patients from memory clinics. Magnetic resonance imaging (MRI), CSF, and plasma samples were collected. Patients were classified as AD+ or non-AD based on the CSF Aβ42/Aβ40 ratio. In the discovery cohort (79 AD+ and 20 non-AD patients with 3D-T1 images), we analyzed the association between WMH volume and plasma PlGF. In the validation cohort (54 AD+ patients without 3D-T1 images), we analyzed the association between WMH grading and plasma PlGF. Among AD+ patients in the discovery cohort, plasma PlGF levels remained significantly associated with WMH volume and grading after adjusting for age, sex, and global cognition. Among the AD+ patients in the validation cohort, the high-PlGF (above median) group had significantly greater WMH volumes and a higher number of patients with a high WMH grading than the low-PlGF (below median) group. Plasma PlGF is a promising marker of cerebrovascular injury in AD.

Indexed as

Alzheimer DiseasePlacenta Growth FactorWhite MatterAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedAmyloid beta-PeptidesBiomarkersPGF protein, humanPlacenta Growth FactorAlzheimer’s diseaseplacental growth factorplasma biomarkerPlGFwhite matter hyperintensity

Identifiers

PMID41154596
PMCPMC12564238

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.